Revusiran

Morgan Stanley’s David N. Lebowitz expects Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares to remain range bound, following the announcement by the company that it was discontinuing its Revusiran program. Lebowitz downgraded the rating on the company from Overweight to Equal Weight, while...

Following, Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) announcing the termination of a late-stage study of Revusiran, citing mortality imbalance, Jefferies said it strongly believes the issue might be program- or disease-specific rather than being overall technology platform-related. Gena Wang, an...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the discontinuation of the development of its late stage pipeline drug, Revusiran due to safety concerns. Goldman Sachs’ Terence Flynn maintained a Neutral rating on the company, while lowering the price target from $65 to $34....